Biofrontera Inc.

Biofrontera Inc. announced its participation in the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026. The company will host a webcast presentation at 11:00 a.m. ET and engage in virtual one-on-one meetings with investors throughout the event. The webcast will also be available for replay.

Biofrontera Inc. reported product revenues of $10.08 million for the first quarter of 2026, a 17.4% increase from $8.59 million in the prior year. The company significantly reduced its net cash outflow from operations to $0.07 million, a substantial improvement from $4.12 million in Q1 2025. Despite these operational improvements, management has raised substantial doubt about the company's ability to continue as a going concern for the next twelve months due to inadequate capital resources. The company also regained compliance with Nasdaq's minimum bid price requirement.

Biofrontera Inc. reported strong financial results for Q1 2026, with revenues increasing 17% year-over-year to $10.1 million and gross margins expanding significantly to 80%. The company also saw an improved operating loss and Adjusted EBITDA, with cash consumption near zero. Operationally, Biofrontera achieved several milestones, including FDA acceptance of its sNDA for Ameluz® PDT for sBCC with a September 2026 PDUFA date, positive Phase 3 results for AK, and positive Phase 2b data for acne.

Biofrontera Inc. announced the launch of its second annual "Hats On Campaign" from May 18 24, 2026, to raise awareness for Actinic Keratosis (AK) and the importance of sun protection. This social media initiative encourages participants to wear a hat, share a photo, and use specific hashtags to highlight AK, which affects an estimated 58 million Americans and has a global prevalence of 14%. Untreated AK can progress to squamous cell carcinoma, a type of skin cancer, with risks increasing over time. The campaign, co-founded by Biofrontera, emphasizes adopting year-round sun-safe habits.

Biofrontera Inc. announced it will report its financial results for the three months ended March 31, 2026, after the close of U.S. financial markets on Thursday, May 14, 2026. The biopharmaceutical company will host a conference call and webcast on the same day at 11:00 a.m. Eastern Time to discuss these results, provide a business update, and answer questions from participants.

Biofrontera Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 11, 2026. Key proposals include the election of two Class II directors, Dr. Hoffman and Mr. Weber, and the approval of an amendment to the 2021 Omnibus Incentive Plan to increase authorized common stock shares from 3,750,000 to 8,750,000. Stockholders will also vote on the ratification of CBIZ CPAs P.C. as the independent auditor for 2026.